CDCA5 (Cell Division Cycle Associated 5), also known as Sororin, is a regulatory protein critical for proper sister chromatid cohesion and separation during mitosis. It stabilizes cohesin complexes on chromosomes after DNA replication, ensuring accurate chromosome alignment and segregation. Dysregulation of CDCA5 is implicated in carcinogenesis, with overexpression observed in cancers like hepatocellular carcinoma, colorectal cancer, and breast cancer, often correlating with poor prognosis, metastasis, and therapeutic resistance.
CDCA5 antibodies are essential tools for studying its biological roles and clinical relevance. These antibodies enable detection of CDCA5 expression and localization via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Researchers use them to explore CDCA5's function in cell cycle control, DNA repair, and tumor progression. For instance, CDCA5 knockdown or inhibition reduces cancer cell proliferation, suggesting its potential as a therapeutic target. Commercially available CDCA5 antibodies are typically validated using recombinant proteins or cell lines to ensure specificity, aiding studies on cancer biomarkers and drug development. Their applications extend to evaluating CDCA5 as a diagnostic or prognostic indicator in clinical samples, further highlighting their importance in oncology research.